Skip to main content
Chugai Pharmabody Research on Muck Rack

Chugai Pharmabody Research

As seen in: EBioMedicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chugai Pharmabody

Contact Chugai Pharmabody, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function

|
By Adrian Ho, Chugai Pharmaceutical, Chugai Pharmabody Research, Ken Ohmine
| EBioMedicine Verified
Keywords Complement C1s C1q Antibody Pharmacokinetic pH-dependent Evidence before this study Aberrant activation of the complement classical pathway (CP) is associated with several autoimmune diseases. Sutimlimab is an anti-C1s antibody drug approved for treatment of patients with cold agglutinin disease, an autoimmune haemolytic anaemia with CP-driven destruction of red blood cells.
Open in Who Shared Issue with article?
See all 1 articles